For millions of diabetics, the greatest dread is not elevated blood sugar but the silent damage it does to their kidneys. When the kidneys fail, patients frequently require lifelong dialysis or a transplant. Now, researchers at the Mayo Clinic claim a new short-course medication that removes dangerous "zombie cells" could potentially delay or even reverse this damage, providing a rare ray of hope for diabetic kidney sufferers. 

The findings, published in The Lancet's journal eBioMedicine, suggest that combining the cancer medicine dasatinib with a plant-based chemical known as quercetin may reduce kidney inflammation and enhance organ function. 

Diabetic kidney disease affects about 12 million Americans and millions more throughout the world. It is the leading cause of renal failure, according to medical professionals. When the disease progresses to its terminal stage, the kidneys lose their ability to filter waste from the blood, forcing patients to rely on dialysis several times per week to survive. 

Until now, doctors could only halt the disease's course by prescribing blood sugar and blood pressure medications. It has been difficult to find a medication that directly targets the biological source of kidney disease, which is crucial for improving patient outcomes and potentially reversing damage. 

The team believes the solution could be to eradicate senescent cells, often known as "zombie cells," which are ageing or wounded cells that have stopped dividing but refuse to die naturally. Instead, they remain in the body, producing poisonous chemicals leading to inflammation and tissue damage.

"Zombie cells act like toxic neighbours," the study's authors noted. "They linger in tissues and gradually damage the surrounding healthy cells." 

To address this issue, scientists used senolytics, a class of chemicals that specifically eliminate defective cells. 

"Our study found that the combination therapy, given over a short period of time, reduced the abundance of senescent cells in a preclinical model of diabetic kidney disease and also improved kidney function," said Dr LaTonya Hickson, a nephrologist at the Mayo Clinic in Florida and the study's principal investigator. 

The trial combined the use of the medication dasatinib with the natural chemical quercetin. Dasatinib is already used to treat certain forms of cancer, while quercetin is a naturally occurring chemical found in apples, onions, and berries. 

The treatment appeared to work by removing senescent cells and lowering the inflammation they generate. When these cells were eliminated, the kidneys demonstrated higher defensive responses and increased function. 

Earlier pilot studies by the same group demonstrated that this combination could diminish senescent cells in the skin and adipose tissues of diabetic renal disease patients. However, the latest study is among the first to show its potential influence on renal tissue. 

"It was important to prove that this one-time, short-course treatment has an effect on the kidneys, and we wanted to do so without invasive procedures in patients," said Dr Xiaohui Bian, the study's principal author. 

In laboratory models of diabetic kidney illness, the therapy reduced not just the quantity of senescent cells, but also inflammation and tissue injury. Tests on cultured human kidney cells yielded similar results. 

Scientists stress that the findings are preliminary and that larger clinical trials will be required before the medication can be widely utilised in patients. However, the findings have sparked much interest since they suggest an entirely new approach to treating chronic renal disease. 

"The results show this combination treatment holds potential to help reduce and halt kidney damage from diabetes," Dr Hickson stated. "Promising findings from these two investigations now suggest that larger-scale studies using senolytics should be pursued in patients to improve kidney health." 

If further trials corroborate the findings, scientists believe the strategy has the potential to improve the management of diabetic kidney disease and minimise the number of individuals who eventually need dialysis, a possibility that millions of patients have long hoped for.